Nexien Financial Statements From 2010 to 2024

NXEN Stock  USD 0.02  0.01  42.86%   
Nexien Biopharma financial statements provide useful quarterly and yearly information to potential Nexien Biopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nexien Biopharma financial statements helps investors assess Nexien Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nexien Biopharma's valuation are summarized below:
Nexien Biopharma does not presently have any fundamental ratios for analysis.
Check Nexien Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nexien Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Nexien financial statements analysis is a perfect complement when working with Nexien Biopharma Valuation or Volatility modules.
  
This module can also supplement various Nexien Biopharma Technical models . Check out the analysis of Nexien Biopharma Correlation against competitors.

Nexien Biopharma Company Return On Equity Analysis

Nexien Biopharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Nexien Biopharma Return On Equity

    
  -40.7  
Most of Nexien Biopharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nexien Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Nexien Biopharma has a Return On Equity of -40.7045. This is 69.81% higher than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is notably higher than that of the company.

Nexien Biopharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Nexien Biopharma's current stock value. Our valuation model uses many indicators to compare Nexien Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nexien Biopharma competition to find correlations between indicators driving Nexien Biopharma's intrinsic value. More Info.
Nexien Biopharma is regarded fourth in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nexien Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nexien Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Nexien Biopharma Financial Statements

Nexien Biopharma investors utilize fundamental indicators, such as revenue or net income, to predict how Nexien Pink Sheet might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Nexien BioPharma, Inc. operates as a pharmaceutical company. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.

Pair Trading with Nexien Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nexien Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nexien Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Nexien Pink Sheet

  0.42LPCUF Lees PharmaceuticalPairCorr
  0.37BRK-A Berkshire HathawayPairCorr
  0.37BRK-B Berkshire HathawayPairCorr
The ability to find closely correlated positions to Nexien Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nexien Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nexien Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nexien Biopharma to buy it.
The correlation of Nexien Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nexien Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nexien Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nexien Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Nexien Pink Sheet

Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.